CiMaas BV:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:CiMaas BV - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11007
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オランダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
CiMaas BV (CiMaas) develops cellular immunotherapies (vaccines) for the treatment of cancer. Its pipeline cellular therapeutic products include CIM101, a dendritic cell vaccine being developed using its proprietary maturation technology for the treatment of lung cancer; and CIM201, a haploidentical natural killer cell product used for the treatment of metastatic breast cancer and multiple myeloma. CiMaas has partnered with the Accelerator Matrix of the Institute for Science and Technology (InSciTe) for the production of vaccines which can treat different types of oncological diseases. It has operations with a manufacturing facility located in Geleen, the Netherlands. The company is a spin-off from Maastricht University Medical Center. CiMaas is headquartered in Maastricht, Limburg, the Netherlands.

CiMaas BV – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
CiMaas BV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
CiMaas BV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
CiMaas BV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
CiMaas BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
CiMaas BV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
CiMaas BV, Pharmaceuticals & Healthcare, Deal Details 10
Private Equity 10
Mercurius and Werker Invest in CiMaas 10
Partnerships 11
CiMaas Enters into Agreement with Cancer Research Technology and University of Copenhagen 11
CiMaas Enters into Agreement with PharmaCell 12
Equity Offering 13
CiMaas Spins Out from Maastricht University Medical Center 13
CiMaas BV – Key Competitors 14
CiMaas BV – Key Employees 15
CiMaas BV – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Recent Developments 17
Corporate Communications 17
May 21, 2018: Alexander Vos appointed to the Supervisory Board of CiMaas 17
Other Significant Developments 18
Oct 06, 2017: CiMaas takes another step forward in treatment for lung cancer 18
Jan 19, 2017: CiMaas starts 2017 with successful first investment 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
CiMaas BV, Pharmaceuticals & Healthcare, Key Facts 2
CiMaas BV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
CiMaas BV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
CiMaas BV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
CiMaas BV, Deals By Therapy Area, 2012 to YTD 2018 8
CiMaas BV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Mercurius and Werker Invest in CiMaas 10
CiMaas Enters into Agreement with Cancer Research Technology and University of Copenhagen 11
CiMaas Enters into Agreement with PharmaCell 12
CiMaas Spins Out from Maastricht University Medical Center 13
CiMaas BV, Key Competitors 14
CiMaas BV, Key Employees 15
CiMaas BV, Other Locations 16

List of Figures
CiMaas BV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
CiMaas BV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
CiMaas BV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
CiMaas BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
CiMaas BV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
CiMaas BV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
CiMaas BV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
CiMaas BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[CiMaas BV:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sany Group Co Ltd:企業の戦略・SWOT・財務情報
    Sany Group Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Sany Group Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Bajaj Finserv Limited:企業の戦略・SWOT・財務情報
    Bajaj Finserv Limited - Strategy, SWOT and Corporate Finance Report Summary Bajaj Finserv Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • PCCW Limited:企業の戦略・SWOT・財務情報
    PCCW Limited - Strategy, SWOT and Corporate Finance Report Summary PCCW Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Duke Energy Corp (DUK):石油・ガス:M&Aディール及び事業提携情報
    Summary Duke Energy Corp (Duke Energy) is an integrated energy utility that undertakes the generation, transmission, distribution and sale of electricity; transportation and sale of natural gas; and provision of related energy services in the Southeast and Midwest regions of the US. It also procures …
  • Aileron Therapeutics Inc (ALRN):製薬・医療:M&Aディール及び事業提携情報
    Summary Aileron Therapeutics Inc (Aileron Therapeutics) is a biopharmaceutical company that discovers, develops, and commercializes novel class of therapeutics. The company provides products such as stapled peptide drugs. Its stapled peptides penetrate cells throughout the body and modulate intracel …
  • Enero Group Limited (EGG):企業の財務・戦略的SWOT分析
    Enero Group Limited (EGG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Nippon Yusen Kabushiki Kaisha (9101):石油・ガス:M&Aディール及び事業提携情報
    Summary Nippon Yusen Kabushiki Kaisha (NYK) is a logistics company. It transports crude oil and allied products. The company provides ocean, land, and air transport services for the transportation of petroleum products, liquid products and dry bulk products. Its portfolio includes linear trade, air …
  • Bend Research Inc-製薬・医療分野:企業M&A・提携分析
    Summary Bend Research Inc (Bend Research), a subsidiary of Capsugel Inc is a provider of drug delivery technologies and formulation development services. The company offers services such as formulation science, dosage form development, process development, engineering, cGMP manufacturing, bioprocess …
  • Tokyo Electric Power Company Holdings Incorporated (9501):電力:M&Aディール及び事業提携情報
    Summary Tokyo Electric Power Company Holdings Incorporated (TEPCO) is an energy utility. It generates, transmits and distributes electricity; transports fuel; and retails electricity and gas. The company produces power using coal, gas, LNG, solar, wind and hydro sources. TEPCO has presence in the en …
  • Forum Energy Technologies, Inc.:戦略・SWOT・企業財務分析
    Forum Energy Technologies, Inc. - Strategy, SWOT and Corporate Finance Report Summary Forum Energy Technologies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Sumitomo Precision Products Co Ltd:企業の戦略・SWOT・財務情報
    Sumitomo Precision Products Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Sumitomo Precision Products Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • ExpressJet Airlines, Inc:企業の戦略・SWOT・財務情報
    ExpressJet Airlines, Inc - Strategy, SWOT and Corporate Finance Report Summary ExpressJet Airlines, Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Intrepid Mines Limited:企業の戦略・SWOT・財務情報
    Intrepid Mines Limited - Strategy, SWOT and Corporate Finance Report Summary Intrepid Mines Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Innovent Biologics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Innovent Biologics Inc (Innovent Biologics) is a biopharmaceutical company that discovers, develops and manufactures monoclonal antibodies. The company offers monoclonal antibodies such as IBI301, IBI302 and IBI303, among others. Its products are used for the treatment of non-Hodgkin’s lymph …
  • HDI-Global SE:企業の戦略・SWOT・財務情報
    HDI-Global SE - Strategy, SWOT and Corporate Finance Report Summary HDI-Global SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Mocon Inc (MOCO):企業の財務・戦略的SWOT分析
    Summary Mocon Inc (Mocon), a subsidiary of AMETEK Inc, is a construction equipment manufacturing company that offers measuring instruments. The company provides permeation testing instruments, microbial detection products, package testing instruments, and physical testing instruments. It offers cons …
  • Capital Lease Aviation Limited:企業の戦略・SWOT・財務分析
    Capital Lease Aviation Limited - Strategy, SWOT and Corporate Finance Report Summary Capital Lease Aviation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Ocular Therapeutix Inc (OCUL):企業の財務・戦略的SWOT分析
    Summary Ocular Therapeutix Inc (Ocular), formerly I-Therapeutix Inc is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for diseases using hydrogel platform technology. The company’s products include DEXTENZA, sustained release travoprost and posterior …
  • Color Genomics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Color Genomics, Inc. (Color) provides physician ordered genetic testing service that helps to identify hereditary cancer risk. The company’s clinical grade test provides actionable results that enable consumers and their doctors to create personalized screening and healthcare plan. Color ana …
  • Sharjah Insurance Company P.S.C.:企業の戦略・SWOT・財務情報
    Sharjah Insurance Company P.S.C. - Strategy, SWOT and Corporate Finance Report Summary Sharjah Insurance Company P.S.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆